



International Symposium:

***Immunostimulatory monoclonal antibodies
and immunomodulation: harvesting the crop***

Fundación Ramón Areces



GENERAL INFORMATION

DATES

OCTOBER 18th-20th

VENUE

University of Navarra. Pamplona, Spain

Modern art museum designed by Rafael Moneo in the University of Navarra main campus (inaugurated in Feb 2015)

ORGANIZERS

Fundación para la Investigación Médica Aplicada – FIMA

Clínica Universidad de Navarra- CUN

SYMPOSIUM COORDINATORS

Dr. Ignacio Melero

Centro de Investigación Médica Aplicada. Clínica Universidad de Navarra. Pamplona

Dr. Juan José Lasarte

Centro de Investigación Médica Aplicada. Pamplona

REGISTRATIONS (FREE OF CHARGE): simposioareces@unav.es



PROGRAM

18th October

16.00-16.30 Opening

Chair: Jesús San Miguel and Juan José Lasarte

16.30-17.15 Ronald Levy

"Targeting the Tumor and Targeting the Host".

Stanford University Medical Center, Stanford, United States

17.15-18.00 Drew Pardoll

"Protumorigenic immunity: the dark side of the immune system".

Johns Hopkins Medical Institutions, Baltimore, United States

18.00-19.00 BREAK

Chair: Ignacio Gil Bazo and Ignacio Melero

19.00-19.45 Jim Allison

"Immune Checkpoint Blockade in Cancer Therapy: New Insights and Opportunities".

MD Anderson Cancer center. Houston. United States

19.45-20.30 Antoni Ribas

"Melanoma response and resistance to PD-1 blockade"

UCLA Medical Center. Los Angeles, California, United States

19th October

Chair: Juan José Lasarte

08.30-09.15 George Coukos

"Understanding tumor microenvironment to optimize immunotherapy. Lessons from ovarian cancer"

University of Lausanne Medical center, Switzerland

09.15-10.00 Ignacio Melero

"CD137 and friends in immunotherapy combinations".

Centro para la Investigación Médica Aplicada-Clinica Universidad de Navarra, Pamplona, Spain

10.00-10.45 Sergio Quezada

"Immune Regulation at the Tumour Site".

UCL Cancer Institute, London, United Kingdom

10.45-11.00 Questions

11.00-11.15 BREAK



Chair: José Luis Pérez Gracia

11.15-12.00 Suzanne Topalian

"PD-1 pathway blockade: a 'common denominator' treatment approach mediates a 'personalized' response".

Johns Hopkins Medical Institutions, Baltimore, United States

12.00-12.45 Mario Sznol

"Immune Therapy of Advanced Melanoma based on Immune Checkpoint Inhibitors".

School of medicine of Yale. New Haven. United States

12.45-13.30 Pam Sharma

"Immunotherapy frontiers against prostate and bladder cancer".

MD Anderson Cancer Center. Houston. United States

13.30-13.45 Questions

13.45-15.30 LUNCH

Chair: Pedro Berraondo

15.30-16.15 Tim Chan

"Cancer genomes and immunotherapy efficacy".

Memorial Sloan Kettering Cancer Center, New York city, United States

16.15-17.00 Sandra Demaria

"Mechanisms of synergy of radiotherapy with antibodies targeting negative immune regulators in the tumor microenvironment".

New York University School of Medicine. New York city, United States

17.00-17.45 Janice Taube

"Tumor markers of response and resistance to PD-1/PD-L1 checkpoint blockade".

Johns Hopkins Hospital. Baltimore. United States

17.45-18.00 Questions

20th October

Chair: Ignacio Melero

08.30- 9.15 Cornelis Melief

"Therapeutic cancer vaccines and their application in combination treatment of cancer"

Leiden University Medical Centre. ISA Pharmaceuticals. Leiden, The Netherlands

9.15-10.00 Caroline Robert

"Melanoma management : New Treatments and new Toxicities"

Institute Gustave Roussy, Villejuif, France

10.00-10.45 John Haanen

"Checkpoint inhibitors: who should we treat?"

The Netherlands Cancer Research Institute. Amsterdam, The Netherlands

10.45-11.00 Questions

11.00-11.15 BREAK



Chair: Pablo Sarobe

11.15-12.00 Francisco Sánchez Madrid

"Leukocyte activation receptor CD69 and ligands: Immunoregulatory role in inflammatory processes".

Hospital de la Princesa. Madrid, Spain

12.00-12.45 Juan José Lasarte

"FOXP3 as a target for Immunotherapy".

Centro para la Investigación Médica Aplicada. Pamplona, Spain

12.45-13.30 María Luisa Toribio

"Therapeutic antibody targeting of human T-cell acute lymphoblastic leukemia initiating cells".

Centro de Biología Molecular Severo Ochoa. Madrid, Spain

13.30-14.15 Mario Colombo

"Multiple layers of immunoregulation: the myeloid connection".

Istituto Nazionale Tumori Experimental Oncology. Milan, Italy

14.15-14.30 Questions

14.30-16.00 LUNCH

Chair: Mario Colombo

16.00-16.45 Rienk Offringa

"A rational approach towards implementation of immunotherapy for pancreatic ductal adenocarcinoma".

German Cancer Research Center, Heidelberg, Germany

16.45-17.30 Christian Ottensmaier

"Genomic assessment of tumour immune profiles in head and neck cancer".

University of Southampton School of Medicine, Southampton, United Kingdom

17.30-17.45 Questions

17.45-18.00 BREAK

Chair: Rienk Offringa

18.00-18.45 Paolo Ascierto

"Combining checkpoint inhibition maximizing the body's immune response to cancers".

Fondazione Pascale Istituto Nazionale Tumori di Napoli, Italy

18.45-19.30 Martin Glennie

" Designing immunostimulatory anti-TNFR mAb to promote anti-cancer immunity".

University of Southampton School of Medicine, Southampton, United Kingdom

19.30-20.15 Questions

20.15 Closing remarks



Additional sponsors:

ASTRA ZENECA



BRISTOL MYERS SQUIBBS



MSD



ROCHE



With the collaboration:

CIMA



CUN



EUFP7 IACT



GETICA



GEIT



REINCA



IdiSNA

